On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
REGULATORY
Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
Japan’s key reimbursement policy panel on October 23 gave a cold shoulder to the pharma industry’s call for giving more flexibility to the selection of comparator products in new drug pricing - a proposal towards the next pricing reform in…
To read the full story
Related Article
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
REGULATORY
- MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures
August 7, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…